KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)

Esperion Therapeutics' Other Non-Current Assets history spans 4 years, with the latest figure at $50.0 million for Q3 2022.

  • For Q3 2022, Other Non-Current Assets changed 0.0% year-over-year to $50.0 million; the TTM value through Sep 2022 reached $50.0 million, changed 0.0%, while the annual FY2021 figure was $50.0 million, N/A changed from the prior year.
  • Other Non-Current Assets reached $50.0 million in Q3 2022 per ESPR's latest filing, roughly flat from $50.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $50.0 million in Q3 2021 to a low of $928000.0 in Q2 2019.
  • Average Other Non-Current Assets over 4 years is $23.3 million, with a median of $1.3 million recorded in 2020.
  • The largest YoY upside for Other Non-Current Assets was 39.44% in 2020 against a maximum downside of 22.21% in 2020.
  • A 4-year view of Other Non-Current Assets shows it stood at $928000.0 in 2019, then soared by 39.44% to $1.3 million in 2020, then surged by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
  • Per Business Quant, the three most recent readings for ESPR's Other Non-Current Assets are $50.0 million (Q3 2022), $50.0 million (Q2 2022), and $50.0 million (Q1 2022).